Last $54.20 USD
Change Today +0.26 / 0.48%
Volume 535.2K
INCY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Paul A. Friedman M.D.

Director, Member of Non-Management Stock Option Committee and Member of Finance Committee, Incyte Corporation
AgeTotal Calculated CompensationThis person is connected to 85 board members in 7 different organizations across 8 different industries.

See Board Relationships
71$2,830,919
As of Fiscal Year 2013

Background*

Dr. Paul A. Friedman, M.D. served as the Chief Executive Officer of Incyte Corporation from November 2001 to January 13, 2014 and also as its President from May 2004 to January 13, 2014. From 1998 to October 2001, Dr. Friedman served as the President of DuPont Pharmaceuticals Research Laboratories, a wholly owned subsidiary of DuPont Pharmaceuticals Company. From 1994 to 1998, he served as President of Research and Development of The DuPont Merck Pharmaceutical Company. ...

Read Full Background

Corporate Headquarters*

Experimental Station
Wilmington, Delaware 19880

United States

Phone: 302-498-6700
Fax: --

Board Members Memberships*

2001-Present
Director, Member of Non-Management Stock Option Committee and Member of Finance Committee
2004-N/A
Former Director and Member of Nominating & Governance Committee
2008-N/A
Director and Member of Compensation Committee
2010-Present
Director and Member of Compensation Committee
2013-Present
Non-Executive Director
2013-Present
Director
2014-Present
Director, Member of Executive Committee and Member of Compensation Committee
2014-Present
Director, Member of Compensation Committee and Member of Nominating & Corporate Governance Committee
2014-Present
Director

Education*

BA 1964
Princeton University
MD 1969
Harvard Medical School

Other Affiliations*

Annual Compensation*

Salary$687,781
Total Annual Compensation$687,781

Stock Options*

All Other Compensation$20,761
Exercised Options400,489
Exercised Options Value$11,382,227
Exercisable Options1,424,629
Exercisable Options Value$57,424,298
Unexercisable Options289,554
Unexercisable Options Value$9,428,447
Total Value of Options$78,234,971
Total Number of Options2,114,672

Total Compensation*

Total Annual Cash Compensation$1,440,911
Total Short Term Compensation$687,781
Other Long Term Compensation$20,761
Total Calculated Compensation$2,830,919
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INCY:US $54.20 USD +0.26

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Harvey J. Berger M.D.Principal Founder, Chairman, Chief Executive Officer, President and Chairman of Executive Committee
Ariad Pharmaceuticals Inc.
$749.8K
Ron Squarer BSc (Biochemistry), MBAChief Executive Officer and Director
Array BioPharma, Inc.
$528.2K
Michael M. Morrissey Ph.D.Chief Executive Officer, President and Director
Exelixis, Inc.
$1.1M
Werner Lanthaler MBA,MPAChief Executive Officer
Evotec AG
€601.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INCYTE CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.